TY - JOUR
T1 - Perspectives in immunotherapy
T2 - Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
AU - Ascierto, Paolo A.
AU - Brugarolas, James
AU - Buonaguro, Luigi
AU - Butterfield, Lisa H.
AU - Carbone, David
AU - Daniele, Bruno
AU - Ferris, Robert
AU - Fox, Bernard A.
AU - Galon, Jérôme
AU - Gridelli, Cesare
AU - Kaufman, Howard L.
AU - Klebanoff, Christopher A.
AU - Melero, Ignacio
AU - Nathan, Paul
AU - Paulos, Chrystal M.
AU - Ruella, Marco
AU - Sullivan, Ryan
AU - Zarour, Hassane
AU - Puzanov, Igor
PY - 2018/7/11
Y1 - 2018/7/11
N2 - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
AB - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
KW - Adoptive cell transfer combination therapy
KW - Biomarkers
KW - Cancer vaccines
KW - Checkpoint inhibitors
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85049861270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049861270&partnerID=8YFLogxK
U2 - 10.1186/s40425-018-0377-z
DO - 10.1186/s40425-018-0377-z
M3 - Review article
C2 - 29996914
AN - SCOPUS:85049861270
VL - 6
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 1
M1 - 69
ER -